The AO Pharma Team
Jonas is a co-founder of AO Pharma. Jonas holds a MSc Pharm from Uppsala University and an MBA from the Stockholm School of Economics and has >20 years of industry experience. Most recently, Jonas was a partner with HealthCap, a life science focused VC. Jonas was a co-founder and the CEO or Wilson Tx (acquired by Alexion for $855m). Prior to HealthCap and Wilson Tx, Jonas held various sales and marketing positions within J&J. Jonas is currently chairman of Tribune Tx and a senior advisor to Pretzel Tx.
Head of Regulatory
Steve Pinder qualified in biochemistry before completing a PhD and post-doctoral work in molecular genetics. Steve has >30 years of regulatory experience from the life science industry. Steve and a colleague founded Envestia, an independent regulatory consulting business. Steve is focused on clinical drug development and regulatory strategy, encompassing drug development planning, scientific advice, orphan drugs and paediatric investigation plans.
Jacob is a co-founder of AO Pharma. Jacob holds a MSc Business Admin & Economics from Lund University and has >25 years of experience from in life sciences venture capital investing and investment banking. Most recently, was a partner at HealthCap, a leading life science focused VC. Jacob Gunterberg has long experience as board member in both private and public companies and is currently chairman of Vicore Pharma Holding AB, board member of Disruptive Pharma Holding AB and Twiceme Technology AB.
Head of Business Development
Former Pharma & Biotech Analyst and Head of Healthcare Equity Research at ABG Sundal Collier. Prior to this Adam worked as a doctor at University College Hospital London, having received a degree in medicine (MBBS) and a BSc in Pharmacology from Imperial College London. Adam also holds a MPhil in Bioscience Enterprise from Queens' College, Cambridge.
Lars in a co-founder of AO Pharma. Lars holds a Ph.D. in organic chemistry from Stockholm University and has >20 years of experience from the industry. Most recently, Lars was responsible for CMC at Guard Tx. Previous engagements include positions with Wilson Tx (acquired by Alexion for $855m), Karo Bio and AstraZeneca.
Head of Market Access
Jonas holds a MSc Pharm from Uppsala University, has a PhD and an associate professorship in health economics from Karolinska Institute. Jonas has >20 years of experience from market access, pricing and health economics, initially from consulting and later from various leadership market access roles within pharmaceutical industry at Nordic and global levels. Examples of previous industry roles include Global Head of Value, Access and Pricing at Oasmia Pharma, Global Head of HEOR for Neuroscience, Rare Diseases and Mature Products at Ipsen, and Head of Value Demonstration and Access, Nordics & Baltics at Shire